Artico, Jessica; Shiwani, Hunain; Moon, James C; Gorecka, Miroslawa; McCann, Gerry P; Roditi, Giles; Morrow, Andrew; ... Greenwood, John P; + view all Artico, Jessica; Shiwani, Hunain; Moon, James C; Gorecka, Miroslawa; McCann, Gerry P; Roditi, Giles; Morrow, Andrew; Mangion, Kenneth; Lukaschuk, Elena; Shanmuganathan, Mayooran; Miller, Christopher A; Chiribiri, Amedeo; Prasad, Sanjay K; Adam, Robert D; Singh, Trisha; Bucciarelli-Ducci, Chiara; Dawson, Dana; Knight, Daniel; Fontana, Marianna; Manisty, Charlotte; Treibel, Thomas A; Levelt, Eylem; Arnold, Ranjit; Macfarlane, Peter W; Young, Robin; McConnachie, Alex; Neubauer, Stefan; Piechnik, Stefan K; Davies, Rhodri H; Ferreira, Vanessa M; Dweck, Marc R; Berry, Colin; OxAMI (Oxford Acute Myocardial Infarction Study) Investigators;; Greenwood, John P; - view fewer (2023) Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study. Circulation , 147 (5) pp. 364-374. 10.1161/CIRCULATIONAHA.122.062508.

Preview

Text 2211.15327.pdf - Published Version Download (645kB) | Preview

Abstract

BACKGROUND: Acute myocardial injury in hospitalized patients with coronavirus disease 2019 (COVID-19) has a poor prognosis. Its associations and pathogenesis are unclear. Our aim was to assess the presence, nature, and extent of myocardial damage in hospitalized patients with troponin elevation. METHODS: Across 25 hospitals in the United Kingdom, 342 patients with COVID-19 and an elevated troponin level (COVID+/troponin+) were enrolled between June 2020 and March 2021 and had a magnetic resonance imaging scan within 28 days of discharge. Two prospective control groups were recruited, comprising 64 patients with COVID-19 and normal troponin levels (COVID+/troponin-) and 113 patients without COVID-19 or elevated troponin level matched by age and cardiovascular comorbidities (COVID-/comorbidity+). Regression modeling was performed to identify predictors of major adverse cardiovascular events at 12 months. RESULTS: Of the 519 included patients, 356 (69%) were men, with a median (interquartile range) age of 61.0 years (53.8, 68.8). The frequency of any heart abnormality, defined as left or right ventricular impairment, scar, or pericardial disease, was 2-fold greater in cases (61% [207/342]) compared with controls (36% [COVID+/troponin-] versus 31% [COVID-/comorbidity+]; P<0.001 for both). More cases than controls had ventricular impairment (17.2% versus 3.1% and 7.1%) or scar (42% versus 7% and 23%; P<0.001 for both). The myocardial injury pattern was different, with cases more likely than controls to have infarction (13% versus 2% and 7%; P<0.01) or microinfarction (9% versus 0% and 1%; P<0.001), but there was no difference in nonischemic scar (13% versus 5% and 14%; P=0.10). Using the Lake Louise magnetic resonance imaging criteria, the prevalence of probable recent myocarditis was 6.7% (23/342) in cases compared with 1.7% (2/113) in controls without COVID-19 (P=0.045). During follow-up, 4 patients died and 34 experienced a subsequent major adverse cardiovascular event (10.2%), which was similar to controls (6.1%; P=0.70). Myocardial scar, but not previous COVID-19 infection or troponin, was an independent predictor of major adverse cardiovascular events (odds ratio, 2.25 [95% CI, 1.12-4.57]; P=0.02). CONCLUSIONS: Compared with contemporary controls, patients with COVID-19 and elevated cardiac troponin level have more ventricular impairment and myocardial scar in early convalescence. However, the proportion with myocarditis was low and scar pathogenesis was diverse, including a newly described pattern of microinfarction. REGISTRATION: URL: https://www.isrctn.com; Unique identifier: 58667920.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item